EIF2AK3 and cancer: In addition, inhibition of PERK-eIF2α axis promotes cell death of therapy-resistant hypoxic glioblastoma and colon carcinoma cells [236], suggesting that combination of cancer therapy and UPR targeting may be desirable for cancer treatment.